STAND. COM. REP. NO. 2198

 

Honolulu, Hawaii

, 2019

 

RE: S.B. No. 1263

S.D. 1

H.D. 1

 

 

 

 

Honorable Scott K. Saiki

Speaker, House of Representatives

Thirtieth State Legislature

Regular Session of 2019

State of Hawaii

 

Sir:

 

Your Committee on Judiciary, to which was referred S.B. No. 1263, S.D. 1, entitled:

 

"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED SUBSTANCES ACT,"

 

begs leave to report as follows:

 

The purpose of this measure is to amend the Uniform Controlled Substances Act to make it consistent with federal law. Specifically, this measure:

 

(1) Includes a Schedule V controlled substance used to treat certain childhood-onset epilepsy patients; and

 

(2) Allows for the use of either words or figures to indicate quantity on electronic prescriptions for controlled substances.

 

The Department of Public Safety, The Queen's Health Systems, Kaiser Permanente Hawaii, Walgreen Co., Greenwich Biosciences, and Epilepsy Foundation of Hawaii testified in support of this measure. Several individuals testified in opposition to this measure. Akamai Cannabis Clinic provided comments.

 

Your Committee has amended this measure by:

 

(1) Changing its effective date to January 28, 2081; and

 

(2) Making technical, nonsubstantive amendments for clarity, consistency, and style.

 

Your Committee notes that testimony suggested repealing language from the Uniform Controlled Substances Act with regard to prescriptions that restricts practicing physician assistants in the State. However, the adoption of this suggestion would be outside of the intended scope of this measure.

 

As affirmed by the record of votes of the members of your Committee on Judiciary that is attached to this report, your Committee is in accord with the intent and purpose of S.B. No. 1263, S.D. 1, as amended herein, and recommends that it pass Third Reading in the form attached hereto as S.B. No. 1263, S.D. 1, H.D. 1.

 

Respectfully submitted on behalf of the members of the Committee on Judiciary,

 

 

 

 

____________________________

CHRIS LEE, Chair